Parkin mitochondrial recruitment assay cell line from Innoprot is based on localization changes of two fluorescent proteins; the Parkin fluorescent fusion polypeptide that changes its localization from the cytosol to the outer mitochondrial membrane (OMM); and the other fluorescent fusion polypeptide (MTS-tGFP), which binds directly to OMM, allowing the mitochondrial integrity analysis.
Several compounds promote Parkin recruitment, but also generate stress and increase cell toxicity. So a good, promising positive compound would be one that promotes Parkin binding to mitochondria to accelerate Parkin protective function but without deeply altering mitochondrial integrity. Our model allows the identification of compounds that can promote the mitochondrial localization of Parkin without severe mitochondrial damage induction.
Parkinson´s disease (PD) is a neurodegenerative disorder that originates with the death of dopamine producing cells in the substantia nigra in the brain. The main sympton is trembling in the hands, legs or face. Most cases of PD are sporadic, but 10% are autosomal dominant or recessive inheritance. Parkin is one of the proteins implicated in one form of familial Parkinson’s disease known as autosomal recessive juvenile Parkinson’s disease (AR-JP). It is a protein that forms part of E3 ubiquitin ligase complex that mediates the targeting of proteins for degradation. The recruitment of parkin by damaged mitochondria occurs during the early stages of mitrophagy.
- This model allows the identification of compounds that inhibit mitochondrial loss of membrane potential through parkin recruitment.
- Parkin Mitochondrial Recruitment Assay Cell Line is a usefull tool to test possible drugs against Parkinson’s disease.
- This model allows to analyse in the space and time the compound effect in a multiparametric manner.